Jayson Punwani

Managing Director at Abingworth

Jayson joined Abingworth’s Menlo Park office in November 2021, bringing with him more than 20 years of experience in venture investing, start-up leadership, technology transfer, and academic research within the life sciences industry.

Previously, Jayson was a Senior Partner at Takeda Ventures, the corporate venture capital arm of Takeda Pharmaceuticals, where he focused on early-stage biotech investments. He led investments in and was on the board of, VelosBio (acquired by Merck), Xilio (NASDAQ: XLO), StrideBio, and Coho Therapeutics. He also served as a member of the board of directors for Armagen (acquired by JCR) and Palleon Pharmaceuticals. Prior to Takeda, Jayson was a Senior Principal at Pappas Ventures where he played a key role in investments in CoLucid (acquired by Eli Lilly), Aura Biosciences (NASDAQ: AURA), Lumena Pharmaceutics (acquired by the Shire), and Glycomine (also an Abingworth portfolio company). He started his career as a research scientist in the cardiovascular drug discovery group at Bristol Myers Squibb.

Location

Menlo Park, United States

Links


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices


Abingworth

1 followers

Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life sciences sectors. Supporting its portfolio companies with a team of 25 at offices in London, Menlo Park, and Boston, Abingworth has invested in 151 life science companies, completed 65 IPOs and 42 mergers and acquisitions.


Industries

Employees

11-50

Links